The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours

In this Insight Article, we explore the future possibilities, challenges, and solutions in peptide purification and the delivery of precision medicine for immunotherapy.

What are the key market trends and challenges facing the Peptides therapeutic industry today? We sat down with an advisory group of leading pharmaceutical and academic experts to discuss our latest Peptides Congress and the interesting insights it disclosed.

Strides made in a landmark phase IIb oral insulin clinical trial.

Christine Rothe, Vice President of Early-Stage-Project Leadership and Data Science at Pieris Pharmaceuticals, presents a case study on Anticalin-antibody fusions for IO.

Could 'Small' Antibody Drug Conjugates Bring Big Advances in Solid Tumour Treatment?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our October Discussion Group addressing ‘Analytical Method Development for Biotherapeutics’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Can biparatopic antibody-drug conjugates enhance cellular trafficking to cancerous tumours? William Olson of Regeneron finds out.

Presented by Richard Blankley, Biopharma Application Specialist, Northern Europe, Agilent Technologies

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. The first of its kind, our September Discussion Group addressing ‘Antibody Discovery, Optimisation & Engineering’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.